Literature DB >> 526385

Ketamine infusions: pharmacokinetics and clinical effects.

J Idvall, I Ahlgren, K R Aronsen, P Stenberg.   

Abstract

The clinical effects and pharmacokinetics of ketamine, administered as an i.v. infusion, were studied in 31 patients. Anaesthesia was induced with ketamine 2 mg kg-1 i.v. and maintained using an i.v. infusion of ketamine, supplemented by nitrous oxide. The plasma concentrations of ketamine, nor-ketamine and dehydro-nor-ketamine were analysed using gas-liquid chromatography. The average maintenance dose of ketamine was 41 +/- 21 microgram kg-1 min-1, but there was an obvious decrease in the dose required as anaesthesia progressed. This dose gave a stable plasma concentration of ketamine of 9.3 +/- 0.8 mumol litre-1. Patients recovered at 2.7 +/- 0.9 mumol litre-1. Plasma half-life of ketamine was 79 +/- 8 min. Maximum concentration of nor-ketamine was 4.7 +/- 2.4 mumol litre-1 and of dehydro-nor-ketamine 3.2 +/- 1.9 mumol litre-1. There were transient increases (15-30% of pre anaesthetic values) in arterial pressure, heart rate and cardiac output during operation. No post-operative respiratory depression was seen.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 526385     DOI: 10.1093/bja/51.12.1167

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  54 in total

Review 1.  General anaesthetic actions on ligand-gated ion channels.

Authors:  M D Krasowski; N L Harrison
Journal:  Cell Mol Life Sci       Date:  1999-08-15       Impact factor: 9.261

Review 2.  When conventional asthma therapies fail.

Authors:  J Jones; S Murin
Journal:  Clin Rev Allergy Immunol       Date:  2001-06       Impact factor: 8.667

Review 3.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

4.  Opioid and non-opioid central cardiovascular effects of ketamine.

Authors:  S Seth; D Mukherjee; A K Choudhary; J N Sinha; S Gurtu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-11       Impact factor: 3.000

5.  Ketamine reduces inducible superoxide generation in human neutrophils in vitro by modulating the p38 mitogen-activated protein kinase (MAPK)-mediated pathway.

Authors:  Huang-Wei Lu; Guan-Nan He; Hong Ma; Jun-Ke Wang
Journal:  Clin Exp Immunol       Date:  2010-03-16       Impact factor: 4.330

6.  Clinical concentrations of chemically diverse general anesthetics minimally affect lipid bilayer properties.

Authors:  Karl F Herold; R Lea Sanford; William Lee; Olaf S Andersen; Hugh C Hemmings
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-06       Impact factor: 11.205

7.  Ketamine as a Prophylactic Against Stress-Induced Depressive-like Behavior.

Authors:  Rebecca A Brachman; Josephine C McGowan; Jennifer N Perusini; Sean C Lim; Thu Ha Pham; Charlene Faye; Alain M Gardier; Indira Mendez-David; Denis J David; René Hen; Christine A Denny
Journal:  Biol Psychiatry       Date:  2015-05-04       Impact factor: 13.382

8.  Continuous subcutaneous injection of ketamine for cancer pain.

Authors:  E Oshima; K Tei; H Kayazawa; N Urabe
Journal:  Can J Anaesth       Date:  1990-04       Impact factor: 5.063

Review 9.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

10.  Ketamine and its preservative, benzethonium chloride, both inhibit human recombinant alpha7 and alpha4beta2 neuronal nicotinic acetylcholine receptors in Xenopus oocytes.

Authors:  K M Coates; P Flood
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.